I think with the news thrown in in August (and put out in an 8K the 24Th) the next logical step for SOAN should be to 'market' on this. I would assume if you enter a license agreement, you want to do something with it. My guess is the next steps will be communicated soon (not months away), hence I've been buying in the 52-70 range quite heavily.
I've seen that this one can move fast, so I'm counting on a quick 30-50% as a minimum when it goes again. Breaking the 141 should not even be a problem and would mean that I can double my money ...
The 8K I'm referring to :
Effective August 23, 2020 the issuer’s subsidiary, SomaCeuticals, Inc. entered into an exclusive global license agreement with 7 to Stand, Inc. for the rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis(MS).
Multiple Sclerosis (MS) is a chronic disease in which the immune system of the individual attacks the central nervous system and affects the nerve cells. The disease can manifest with a wide range of neurological symptoms and can progress to total physical and cognitive disability. There are many different symptoms of MS, including fatigue, numbness, walking and balance problems, bladder dysfunction, bowel dysfunction, vision problems, dizziness and vertigo, sexual dysfunction, pain, cognitive dysfunction, emotional changes, depression and spasticity.
There is no known cure using current treatments and is the most common immune-mediated disorder affecting the central nervous system. With over 2.3 million people affected and with each individual spending approximately $70,000 per year, MS ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in 2016, representing nearly $19 billion in drug spending alone.
News 
Market Data 
Discover 
